Closed Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES

    Notice of Intent to Sole Source – BIONANO GENOMICS, INC

    Sol. NOI-CC-25-009351Special NoticeBETHESDA, MD
    Closed
    STATUS
    Closed
    POSTED
    Sep 2, 2025
    Publication date
    NAICS CODE
    334516
    Primary industry classification
    PSC CODE
    6640
    Product & service classification

    AI Summary

    The Department of Health and Human Services intends to sole source reagents from Bionano Genomics, Inc. for the Optical Genome Mapping assay. This procurement is essential for detecting chromosomal abnormalities in patient samples, particularly in cancer diagnostics. The acquisition follows FAR Part 13 Simplified Acquisition Procedures, allowing for a single source solicitation.

    Contract details

    Solicitation No.
    NOI-CC-25-009351
    Notice Type
    Special Notice
    Posted Date
    September 2, 2025
    Response Deadline
    NAICS Code
    334516AI guide
    PSC / Class Code
    6640
    Contract Code
    7529
    Primary Contact
    Chris Ryssa Nix
    State
    MD
    ZIP Code
    20892
    AI Product/Service
    product

    Description

    This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. This procurement is for reagents for the Bionano Optical Genome Mapping (OGM) assay for testing samples from patient. Bionano OGM instrument and assay are used to perform optical genome mapping of patient samples to detect chromosomal, cytogenetic, and structural abnormalities that are often missed by other molecular technologies such as cytogenetics, fluorescence in situ hybridization (FISH), or next generation sequencing (NGS). Bionano is the original reagent manufacturer and sole vendor for instruments of these kinds of tests, i.e., optical genome mapping to detect large deletions and cytogenetic abnormalities, copy number abnormalities, and small structural variants from patient samples. It is advisable to use OGM for testing of samples from patients with cancer, cancer predisposing disorders, and with complicated clinical and pathological phenotypes. Furthermore, the instrument obtained from the vendor will be available to other researchers in the Clinical Center and potentially validated for clinical testing purposes. This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 –Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government. Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Ryssa Nix, Contract Specialist via email to Ryssa.nix@nih.gov by close date.

    Key dates

    1. September 2, 2025Posted Date

    AI search tags

    Frequently asked questions

    Notice of Intent to Sole Source – BIONANO GENOMICS, INC is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.

    SamSearch Platform

    Stop searching. Start winning.

    AI-powered intelligence for the right opportunities, the right leads, and the right time.